



Royal Netherlands Academy of Arts and Sciences (KNAW) KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN

Intracranial electrophysiological biomarkers of compulsivity in obsessive–compulsive disorder

Arbab, Tara; Bais, Melisse N.; Figeo, Martijn; Bergfeld, Isidoor O.; Schuurman, P. Richard; van den Munckhof, Pepijn; Willuhn, Ingo; Denys, Damiaan

published in

Nature Mental Health
2025

DOI (link to publisher)

[10.1038/s44220-025-00457-9](https://doi.org/10.1038/s44220-025-00457-9)

document version

Publisher's PDF, also known as Version of record

[Link to publication in KNAW Research Portal](#)

citation for published version (APA)

Arbab, T., Bais, M. N., Figeo, M., Bergfeld, I. O., Schuurman, P. R., van den Munckhof, P., Willuhn, I., & Denys, D. (2025). Intracranial electrophysiological biomarkers of compulsivity in obsessive–compulsive disorder. *Nature Mental Health*, 3, 889–898. <https://doi.org/10.1038/s44220-025-00457-9>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the KNAW public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the KNAW public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

pure@knaw.nl

Intracranial electrophysiological biomarkers of compulsivity in obsessive–compulsive disorder

Received: 14 October 2024

Accepted: 27 May 2025

Published online: 24 July 2025

 Check for updates

A list of authors and their affiliations appears at the end of the paper

There is an emerging need for objective neural biomarkers of obsessive–compulsive disorder (OCD) to improve the efficacy of neuromodulatory interventions, most notably deep-brain stimulation (DBS), and develop closed-loop stimulation paradigms. Preliminary data suggest that such biomarkers may be derived from local field potentials (LFPs) recorded in individual patients implanted with sensing DBS devices. However, reliable LFP signatures that are generalizable across OCD patients have yet to be identified. Here, we relate LFPs recorded from sensing DBS electrodes in different basal-ganglia structures to core symptoms of OCD in 11 patients during personalized provocation of obsessions and compulsions. We identify two general markers of compulsion: delta and alpha LFP power was significantly increased during all compulsions in the external globus pallidus (GPe), nucleus accumbens, anterior limb of the internal capsule (ALIC) and anterior lateral anterior commissure. In mental compulsion subtypes, similar low-frequency increases were observed only in GPe (delta/alpha) and ALIC (alpha), suggesting that these signals possibly reflect more universal biomarkers of compulsivity unconfounded by motor function. GPe delta power correlated with OCD symptom severity, establishing a meaningful connection between subcortical sensing DBS readout and patient experience. ALIC alpha power was modulated by the phase of theta oscillations during compulsions, possibly reflecting pathological coupling of cortical networks in OCD. Our results demonstrate unique, group-level LFP correlates of core OCD symptoms across disease-relevant basal-ganglia structures. These electrophysiological signatures help pave the way toward the development of biomarker-targeted neuromodulatory intervention for OCD. Netherlands Trial Register ID: [NL7486](#).

Obsessive–compulsive disorder (OCD) is a debilitating psychiatric disorder characterized by persistent, unwanted intrusive thoughts (obsessions) and corresponding repetitive, ritualistic behaviors (compulsions). Although the majority of patients can be treated to a satisfactory level with pharmacotherapy and behavioral therapy, approximately 10% of patients respond insufficiently and remain severely ill¹. In these therapy-resistant patients, neuromodulation using deep-brain stimulation (DBS) can be highly effective, leading to response rates of 52–66% (refs. 2,3).

DBS entails neurosurgical implantation of intracranial electrodes to target specific brain areas with electrical pulses, modulating activity of local and connected neuronal networks. In therapy-resistant OCD, common DBS targets are the internal capsule, the nucleus accumbens (NAc) and the subthalamic nucleus^{4,5}. These structures relate to the cortico-striato-thalamo-cortical (CSTC) circuit, in which aberrant neuronal network activity is hypothesized to underlie OCD^{6–11}. However, the exact physiological manifestation of OCD in CSTC structures is yet

✉ e-mail: t.arbab@amsterdamumc.nl; d.denys@amsterdamumc.nl

Table 1 | Patient demographics and experiment details

Demographics			During experiment		
Gender	Handedness	Y-BOCS score	OCD subtype	Obsessions induced by	Compulsion behavior
F	Left	8+7 ^a	Contamination	Touching the floor	Washing hands
F	Right	18+18	Religious	Reading a religious text	Praying ^b
F	Right	18+17	Contamination/checking	Touching the floor	Washing hands
F	Right	19+18	Contamination/checking	Others touching a personal object brought from home	Inspecting ^c the object
F	Right	19+20	Contamination/symmetry	Touching the floor	Washing hands
F	Right	17+19	Harm/checking	Thinking about a fire risk	Checking whether there is a fire
F	Right	17+16	Contamination/symmetry	Touching the floor	Washing hands
F	Right	17+16	Contamination	Touching the door knob/light switch	Washing hands
F	Right	16+19	Harm/contamination	Thinking about a personal contaminated object	Checking photographs to see the object is clean
M	Right	11+11	Religious	Reading a religious text	Reading a reassuring text
F	Right	17+16	Contamination	Touching the floor	Washing hands

F, female; M, male. Yale–Brown Obsessive Compulsive Scale (Y-BOCS) scores are displayed as obsessions + compulsions. ^aThis patient had already undergone DBS treatment and was recruited into the current study after a replacement of the device battery. The original clinical Y-BOCS score was 38. ^bThis patient occasionally wrote. ^cThis patient occasionally washed the object.

to be discovered, and approximately 30–50% of patients experience partial or inadequate response to DBS, remaining severely disabled in daily functioning².

Improved understanding of electrophysiological activity throughout CSTC networks could improve clinical outcomes of neuromodulatory interventions such as DBS^{12–14}. Novel technological advances allow real-time recording of intracranial brain activity (neuronal oscillations), time-locked to behavioral states, directly from DBS electrodes, from which neural correlates of OCD may be obtained. These oscillations, derived from the local field potential (LFP), are extracellular electrical signals that reflect temporal coordination of neuronal activity¹⁵. The frequency and amplitude of this synchronized neuronal network activity has been functionally linked with cognitive and mechanistic processes throughout the brain, such as neuronal communication and information processing^{16,17}; furthermore, abnormal LFP oscillations have been linked with pathological neuronal activity in modeled psychiatric disease¹⁸. As altered communication between cortical- and basal-ganglia structures is thought to underlie OCD¹⁹, we hypothesized that OCD symptoms would be reflected as compromised LFP in these networks. Indeed, case reports^{20–24} characterizing neural correlates of OCD provide insight into possible neuronal signatures on the level of individual patients, and, in a recent publication from our team, deep-learning models based on LFP recordings from individual patients could identify different symptom states whereas models based on (group-level) data from multiple patients could not²⁵. However, targeted intervention for OCD symptoms (using neuromodulation such as so-called closed-loop DBS, where stimulation adapts directly to intervene with detected pathological neural activity) requires general, group-level disease biomarkers.

Here, we present LFP data from 11 sensing-DBS-implanted OCD patients, recorded in basal-ganglia nuclei and associated white matter, aiming to discover electrophysiological correlates related to cardinal features of OCD across patients and brain regions. We employed a behavioral task that effectively evoked core symptoms, imitating real-life brain states in which patients might benefit from improved neuromodulatory intervention, and identify general disease biomarkers throughout the basal ganglia and associated white matter.

Results

Eleven patients with treatment-resistant OCD indicated for DBS were included in this study over a period of 5 yr. Patient demographics

are summarized in the left-hand panel of Table 1. All patients were implanted bilaterally in the brain with a Medtronic DBS system and leads. The experiment took place after recovery from surgery. After a 3-min baseline (BAS) in which patients watched a neutral movie, during which LFP was recorded from the DBS electrodes, patient-specific obsessions (OBS) were provoked and LFP was recorded for 3 min in this obsessive state. Subsequently, patients performed their compulsions (COM), while LFP was recorded for at least 3 min, until patients reported their urge had subsided. Finally, 3 min of LFP was recorded as patients experienced relief (REL). Severity of obsession, compulsion, agitation, anxiety, depressive mood and avoidance was quantified throughout the experiment by patient-reported visual analog scale (VAS) scores (Fig. 1a). Provocation of obsessions sharply increased severity of obsession, compulsion, agitation and anxiety compared with baseline, as reflected in the VAS scores in Fig. 1a. This severity remained stable throughout the obsession recordings, and decreased during compulsions, returning to baseline levels during relief recordings. Thus, the symptom provocation was successful in inducing the intended effect. Patient-specific obsessions and compulsions are summarized in the right-hand columns of Table 1.

Representative LFP traces recorded during each of the four behavior states in Fig. 1b illustrate reliable neural signal with the presence of delta, theta and alpha oscillations. Lead implants were localized for each individual patient in basal ganglia and associated white matter illustrated in Fig. 1c. We included only data recorded from electrode pairs that could be unambiguously localized in the anterior limb of the internal capsule (ALIC, $n = 10$), the most anterior portion of the external globus pallidus (aGPe, $n = 12$), a slightly more posterior part of the anterior external globus pallidus (pGPe, $n = 17$), the most anterior portion of the lateral anterior commissure (alAC, $n = 6$) or the NAc ($n = 5$) (Fig. 1d); the remaining ($n = 16$) electrode pairs were excluded from analysis as their placement fell wholly or partially across anatomical borders.

Time–frequency representation of continuous LFP recordings averaged across all patients during each behavior state demonstrates that the baseline power of low-frequency oscillations differed between anatomical recording locations but increased in all brain regions during performance of compulsions (Fig. 2a). This compulsion-driven LFP power increased significantly from baseline across multiple frequencies in all brain regions (Fig. 2b, non-parametric randomization test $P < 0.05$; Extended Data Table 1), extending heterogeneously over multiple frequency bands (Fig. 2c, Bonferroni-corrected one-way

analysis of variance (ANOVA) with Dunnett’s multiple-comparison test; Extended Data Table 2). Thus, compulsions in OCD were marked by generally increased delta and alpha LFP power throughout all structures evaluated in our study, whereas increased theta, beta and gamma LFP power during compulsions was regionally distinct. Low-frequency LFP power was also significantly increased in ALIC during post-compulsion relief (Fig. 2b,c), though we cannot exclude that this was confounded by mental compulsions persisting at the start of the relief phase in one patient (which can be seen in Fig. 2a, top right panel).

As increased delta/alpha power during compulsions was observed in all brain regions, we further determined whether these signals could serve as universal compulsivity markers across the CSTC circuit. First, considering that the basal ganglia facilitate movement, we discerned to what extent our LFP signals reflected the motor component of compulsions, by dividing the data set to compare powers of delta and alpha oscillations in patients with compulsions requiring movement (for example, hand washing) and patients with non-motor/mental compulsions (for example, praying). Increased delta power during non-motor/mental compulsions persisted only in ALIC and GPe, indicating that these signals may universally mediate compulsive feelings, thoughts and actions (Fig. 2d, Bonferroni-corrected unpaired *t*-test; Extended Data Table 3); however, this signal did not persist in NAc, indicating here it may mediate only the motor-action component of compulsions, or reflect general movement. Non-motor compulsive alpha power was only increased in pGPe (Fig. 2d, Bonferroni-corrected unpaired *t*-test; Extended Data Table 4). The compulsions of all patients in the aLAC group required action, so although motor-compulsion signals significantly differed from baseline in both delta and alpha bands (Fig. 2d, Bonferroni-corrected unpaired *t*-test; Extended Data Tables 3 and 4), we could not determine to what extent these signals reflect compulsive feeling.

Next, we explored the correlation between delta/alpha power and self-reported severity of obsessions, compulsions, agitation, anxiety, depressive mood and avoidance during symptom provocation in ALIC, aGPe and pGPe (that is, the regions mediating compulsive feeling). During obsessions the aGPe delta-power increase correlated positively with obsession severity (Fig. 1a: $[LFP_{Obsession} - LFP_{Baseline}]$, $[VAS_{Obsession(Time-point4)} - VAS_{Obsession(Time-point2)}]$; Fig. 2e: Pearson $r(5) = 0.77$, 95% confidence interval 0.03093 to 0.9634, $P = 0.044$), while during compulsions the aGPe delta-power increase showed a non-significant negative correlation with anxiety severity (Fig. 1a: $[LFP_{Compulsion} - LFP_{Obsession}]$, $[VAS_{Anxiety(Time-point6)} - VAS_{Anxiety(Time-point4)}]$; Fig. 2e: Pearson $r(5) = -0.70$, 95% confidence interval -0.9522 to 0.1053 , $P = 0.078$). We found no significant symptom-severity correlations with LFP power in pGPe (delta/alpha) or ALIC (delta).

Finally, despite it being general throughout the brain regions evaluated in our study, compulsion-mediated delta-power increase showed a defined spatial distribution across all recording sites (Fig. 2f), with highest baseline-subtracted power advancing non-uniformly from NAc and ALIC into GPe. This further corroborates delta-power increase as anatomically specific (rather than general, volume-conducted) and consequential to OCD symptomatology.

As LFP oscillations reflect temporal coordination of neuronal activity, interaction of these oscillations across frequency bands may play




Fig. 1 | Intracranial electrophysiological recordings during symptom provocation in OCD. **a**, OCD symptoms were successfully induced by our provocation paradigm. Patients ($n = 11$) reported VAS scores reflecting the experience severity of obsession, compulsion, anxiety, agitation, depression and avoidance at seven timepoints throughout symptom provocation (mean \pm s.e.m.). Three minutes of LFP was recorded during each behavioral condition: during ‘baseline’ patients watched a neutral movie while seated in a chair; during ‘obsession’ and ‘compulsion’ they respectively experienced and performed their patient-specific obsessions and compulsions; during ‘relief’ they were again seated in a chair. Additional compulsion LFP was recorded if the patient could not cease this behavior after 3 min. **b**, Example LFP traces recorded during symptom provocation. Top rows show full-spectrum LFP, bottom rows show the same trace filtered for different frequency bands. **c**, Anatomical localization of the DBS leads (Medtronic 3389, orange) from which LFP was recorded in one example patient, illustrating in coronal view the basal-ganglia nuclei (GPe, NAc) and associated white-matter structures (ALIC (shown only unilaterally), aLAC) that were targeted in this study. **d**, Highlighted (in red) Medtronic 3389 contact electrodes from which LFP was recorded in this study projected onto one hemisphere, separated per anatomical target, shown in reference to GPe (blue structure; in lateral, frontal and medial views).

an important role in cognitive processes²⁶. Thus, we hypothesized that so-called phase–amplitude coupling (PAC) of subcortical neural oscillations may be disturbed in repetitive, compulsive behavior. To explore this, we calculated the cross-frequency coherence of LFP in basal ganglia and associated white-matter regions during symptom provocation (Fig. 3a). We further explored the striking signal observed in ALIC, and determined that PAC in this region was significantly stronger than semi-randomized PAC during compulsion ($P = 0.022$) but not baseline, obsession or relief states. Three of these ALIC–compulsion cross-frequency interactions (as outlined in Fig. 3b: theta–alpha (5–6 Hz, 9–11 Hz), theta–beta (5–6 Hz, 17–24 Hz) and beta–gamma (13–22 Hz, 30–40 Hz)) were selected for further analysis (note that the prominent 15–30 Hz coupling likely reflects interactions within the beta band itself). Only theta–alpha mean PAC was significantly stronger during compulsions compared with baseline in ALIC (Fig. 3c, one-tailed Wilcoxon signed-rank test, $Z = -1.89$, $P = 0.030$).

Discussion

Discovering electrophysiological disease markers of OCD is critical for improving outcomes of neuromodulatory interventions such as DBS. Here, we have identified intracranial electrophysiological correlates of several cardinal features of OCD across cortico-striatal network nodes. Crucially, as an essential control lacking from many study designs, in our study we control for the contribution of movement during compulsions, differentiating between brain regions where increased LFP power relates to compulsive feeling from those where it relates to (compulsive) action.

Using the Lead-DBS toolbox²⁷ to reconstruct, visualize and localize the DBS leads in each patient individually, combined with additional verification and refinement of electrode locations, we determined that our LFP data were recorded from brain structures whose functions fit in the line of evidence that CSTC-circuit dysfunction is the core pathophysiology of OCD. As a key node in this system, the GPe can be subdivided into (anterior) limbic, (medial) associative and (posterior) sensorimotor functional territories^{28,29}. Our recordings target the most anterior, limbic portion of GPe, which is speculated to be of therapeutic relevance for psychiatric disorders, and where disruption of inhibitory neurotransmission is shown to induce stereotypies in primates³⁰. Yet, this delineation may be more complex. Thus, for the purpose of this study, we took the additional step of subdividing our GPe recording sites into more anterior (aGPe) and more posterior (pGPe) parts of anterior GPe, and indeed find subtle divergence of electrophysiological signatures in our most anterior and more posterior subdivisions of anterior GPe.

Although compulsions increased the power of delta oscillations from baseline across all brain areas targeted in our study (which generalizes to the $n = 16$ electrode pairs that were excluded from analysis due to anatomy; Extended Data Fig. 1), qualitative differences between them imply that this signature was not simply volume-conducted from a single brain region: its spatial distribution was regionally distinct

across recording sites, it persisted only in a subset of brain regions during compulsions that were not implicitly linked to physical movement and it correlated with experience of symptom severity only in aGPe. Thus, our data suggest that subcortical delta oscillations are meaningfully different across basal-ganglia structures and that they can reflect compulsivity beyond their purported role in mediating compulsive movements. Alpha-oscillation power similarly increased in all brain areas during compulsions, yet only related to non-motor/mental compulsions in pGPe, and did not correlate with symptom severity. Increased power of theta and beta oscillations during compulsions was region specific, and phase–amplitude interactions were only affected in ALIC. This heterogeneity of our findings across frequency bands and brain regions suggests that we have identified several distinct potential biomarkers that may reflect disparate behavioral aspects of OCD symptomatology.


Understanding of the functional relevance of subcortical oscillatory frequencies in psychiatric disease is limited, as only recent advances have made it possible to record deep-brain LFP in chronically implanted patients. However, human electroencephalography (EEG) studies have linked global, cortical delta activity to motor preparation and transfer of sensory information^{31–33}. Delta activity may be particularly suited for this type of communication, as its low-frequency oscillations provide long time windows, allowing larger ensembles of neurons to synchronize their activity, with resulting large oscillation amplitude that may facilitate interaction between distant brain regions. This mechanism may mediate psychiatric symptoms across the CSTC circuit, that is, we speculate that the increased delta power observed in our study reflects compulsive feeling by strongly coupling neuronal activity in basal-ganglia nuclei and cortical areas.

A compelling characterization of OCD posits compulsions as goal-directed actions to mitigate the anxiety induced by obsessions³⁴. In this sense, it is unexpected that we did not find obsessions to be represented in deep-brain structures as robustly as compulsions. One interpretation is that obsessions are more strongly represented elsewhere in the brain, and thus, in our study, we identified only the subcortical reflection of this activity. Following an alternative model of OCD, where pathological disinhibition of the prefrontal cortex allows habits to escalate into compulsions, obsessions are interpreted as patients' post hoc rationalization of their behavior, instead of a driving force³⁵. The construct of our study, where obsession and compulsion states were induced separately and in sequence, precludes us from interpreting the relevance of this latter model in our data.

One origin of the LFP signal is synchronization of neuronal post-synaptic potentials by afferent activity¹⁵; in the OCD-CSTC circuit, increased subcortical LFP power may therefore reflect pathological cortical inputs³⁶, which renders the circuit inflexible, resulting in compulsive behavior. Indeed, our team has previously shown that NAc DBS in OCD attenuates symptom-provocation-increased low-frequency frontal EEG power⁸. More recent work in OCD patients has identified connectivity between the NAc and frontal cortex in theta and alpha

Fig. 2 | Neuronal correlates of OCD. **a**, Averaged time–frequency power spectra of the 27-s continuously recorded LFP segments in each brain region, during the experimental states. Low-frequency oscillations increased in all brain regions during compulsions. **b**, Power spectra (mean \pm s.e.m.) of LFP recorded during the experimental states in each brain region. Colored, horizontal lines at the top of the graphs mark the frequencies at which the spectral power of obsession, compulsion and relief LFP significantly differed from baseline (two-tailed non-parametric randomization test, $P < 0.05$). **c**, Bar graphs (mean \pm s.e.m.) of spectral LFP power per frequency band during the experimental states in each brain region. Pairwise comparisons mark power during obsession, compulsion and relief significantly different from baseline (Bonferroni-corrected one-way ANOVA with Dunnett's multiple-comparison test). Delta and alpha powers are increased during compulsions in all brain regions. **d**, Baseline-subtracted power spectra (mean \pm s.e.m.) of LFP recorded during motor and non-motor

compulsions in each brain region. Pairwise comparisons in bar graph insets (mean \pm s.e.m.) mark significantly different delta and alpha powers from baseline during (non-)motor compulsions (Bonferroni-corrected two-tailed unpaired t -test). **e**, Correlation and linear regression between aGPe delta power and VAS scores for obsession and anxiety during obsession and compulsion conditions. aGPe delta power significantly increased with experience of obsession during the induction and experience of obsessions (Pearson $r(5) = .77$, $P = 0.044$), whereas aGPe delta power decreased (non-significant) with reduced anxiety on performing compulsions (Pearson $r(5) = -0.70$, $P = 0.078$). **f**, Anatomical distribution of baselined delta power during compulsions across all recording sites mirrored onto one hemisphere, shown with reference to GPe (in lateral, ventral and medial views), illustrating highest power localized in NAc, ALIC and aGPe. **** $P < 0.0001$, *** $P < 0.001$, ** $P < 0.005$. a.u., arbitrary units.



In fact, immediate effects of DBS typically affect patient mood, anxiety and confidence before alleviating obsessions and compulsions, and it is therefore possible that, despite our characterization of the behavior states in our paradigm as ‘obsessive’ or ‘compulsive’, the neural correlates we find reflect more subtle representations thereof. For instance, our correlation of delta power with obsession severity is similar to the reported low-frequency power increase immediately preceding loss-of-control eating⁵³, and our corresponding delta-power and anxiety decrease during compulsions is similar to the reported delta-power decrease with OCD symptom intensity²²; these findings might be different classifications of the same neural signal. Moreover, as Fig. 2e illustrates, neural signals during compulsions may relate to more than just the compulsions themselves, reflecting reduction in VAS anxiety. In the same vein, it is possible that our choice of VAS to monitor throughout symptom provocation does not accurately reflect patients’ experience of their symptomatology; for instance, basal-ganglia LFP might correlate more strongly with feelings of distress or disgust elicited during symptom provocation, which were not evaluated in our study.

Furthermore, we chose to restrict our analyses to recordings taken from electrode pairs localized within CSTC structures, thus defining our results on the basis of current understanding of presupposed networks of OCD. It is, however, possible that LFP recorded differentially from a combination of brain regions could reveal other signatures of OCD dynamics not identified in our study. Additionally, as an exploratory study, our results must be replicated in a hypothesis-driven manner to verify how these biomarkers reflect OCD symptoms, and whether they can be used successfully as triggers for closed-loop DBS or other neuromodulatory intervention. Finally, although we controlled for the effects of movement on neuronal correlates of compulsion by separately analyzing patients on the basis of their motor activation, future experiments would benefit from a more comprehensive characterization of movement effects on basal-ganglia LFP by controlling for non-compulsive movement-related neuronal activity.

Ultimately, we describe here an approach to identifying intracranial biomarkers of psychiatric disease using an unprecedentedly large group of patients that is innovative in multiple aspects: the data were recorded from electrodes that can be directly implemented for treatment, the behavioral paradigm was individually tailored to each patient and we differentiated our data between multiple brain areas due to highly refined anatomical localization of our recording sites. With this paradigm we found novel, group-level neural signatures of OCD obtained from sensing DBS recordings, which may prove invaluable in the pursuit of biomarker-targeted neuromodulatory intervention.

Methods

Participants

Between June 2015 and March 2020, 11 patients with treatment-resistant OCD indicated for DBS were recruited at the outpatient clinic of the psychiatry department of the Amsterdam UMC, location AMC. The study was approved by the Medical Ethics Committee of the Academic Medical Center, University of Amsterdam, and registered in the Netherlands Trial Register under trial number NL7486, <https://onderzoekmetmensen.nl/en/trial/50295>. Before participation, all patients provided written informed consent.

Participants included in the study met the following inclusion criteria: primary diagnosis of OCD according to DSM and indication for DBS implantation. This patient group was defined as treatment resistant with insufficient response to at least two treatments with a selective serotonin reuptake inhibitor at maximum dosage for >12 weeks, one treatment with clomipramine at maximum dosage for >12 weeks and at least one augmentation trial with an atypical antipsychotic and a selective serotonin reuptake inhibitor for 8 weeks. In addition, patients must have undergone one cognitive behavioral therapy trial at an OCD expert center, involving individual sessions, group day treatment or

admission². Patients were included following a new indication for DBS (ten patients) or an indication for stimulator replacement after successful DBS (one patient). Patients were excluded from the study in the case of substance or alcohol abuse 6 months before participation.

DBS-implantation surgery

Implantation of the DBS system was performed under general anesthesia. Frame-based magnetic resonance imaging (MRI) was used for target determination. A detailed description of the surgical procedure was previously reported². In short, Medtronic model 3389 leads (used off-label) with four contact electrodes (each 1.5 mm in length, spaced 0.5 mm apart, with 7.5 mm total spread) were implanted bilaterally in the brain, following the ALIC, with the most ventral contact targeting the NAc (Fig. 1c). The leads were connected via subcutaneous Medtronic extension cables to an Activa PC + S sensing neurostimulator (Medtronic model 37604, used off-label), which was placed in the right infraclavicular pocket. This telemetry device is able to both stimulate and record LFP at its contact electrodes. Patients received standard medical care after the procedure.

Study design

The experiment was conducted in the clinic once patients had recovered from surgery, which was two to three weeks after device implantation, before the DBS system being activated. In two exceptional cases, recordings were done after DBS had already been activated; stimulation was temporarily turned off (an hour beforehand) for these recordings.

Recordings were done during a symptom-provocation task in which patients experienced and performed, respectively, their patient-specific obsessions and compulsions (Fig. 1a, as previously reported²⁵): 3 min of LFP was recorded during four behavioral states (baseline, obsession, compulsion, relief). Appropriate personalized symptom-provocation methods were selected in consultation with the patient before the experiment.

During the 3-min baseline recordings, patients were asked to sit still and watch a neutral movie. This was followed by personalized obsession provocation (for example, touching the floor in case of contamination fear), after which patients were asked to sit still and experience their obsessions for another 3-min LFP recording. Subsequently, patients were allowed to perform their compulsions (for example, washing their hands in case of contamination fear) while LFP was recorded for 3 min or longer, until their urge resolved. Finally, patients were asked to sit still and experience their relief for another 3-min LFP recording. All but one patient underwent four iterations of the entire protocol.

Outcome measures

Neural activity was recorded using the 8180 Sensing Programmer SW (Medtronic) in montage mode, obtaining LFP differentially between two electrodes for 30 s each in succession, across all six electrode combinations on the lead, simultaneously in both hemispheres (sampling rate 422 Hz, gain 2,000, bandpass filtered 0.5–100 Hz).

Severity of obsession, compulsion, agitation, anxiety, depressive mood and avoidance was monitored throughout the experiment at the beginning and end of each behavioral state using a VAS, on which patients rated each from 1 to 10 (where higher scores imply more severe symptoms, Fig. 1a).

The Y-BOCS⁵⁴ was used to measure the severity of OCD symptoms pre-surgery, providing insight into the clinical status of the participants during the experiment (scores are divided into obsessive and compulsive subscores, with a total score range from 0 to 40, where higher scores imply more severe symptoms). Demographic, clinical and experimental details of the study group are summarized in Table 1 (as previously reported²⁵). Patient age range was 32–68 years (mean 49, s.d. 10.9).

Anatomical localization

The position of the implanted DBS leads was verified using the Lead-DBS toolbox v.2.5.2²⁷ in MATLAB R2021a (MathWorks). In short, post-operative stereotactic computerized tomography was merged with preoperative T_1 MRI using a two-stage linear registration (rigid followed by affine) as implemented in Advanced Normalization Tools⁵⁵ for each patient individually. Coregistered scans were inspected, refined, corrected for postoperative brain shift as needed and subsequently normalized into ICBM 2009b nonlinear asymmetric MNI space⁵⁶ using the SyN-registration approach as implemented in Advanced Normalization Tools. DBS electrodes were automatically pre-reconstructed in native and template space using the PaCER algorithm⁵⁷, visually inspected and manually refined as needed. Anatomical localization of each pair of adjacent electrodes was determined using an adaptation of the DISTAL atlas⁵⁸ in Lead-DBS, after which results were visually verified to individual patient computerized tomography–MRI coregistered electrode trajectories, and refined using two additional atlases^{59,60}. The Lead-Group toolbox v.2.5.2⁶¹ was used to visualize recording sites (Fig. 1c,d) and the distribution of baseline-subtracted delta power onto them (Fig. 2f), using an adaptation of the DISTAL atlas⁵⁸.

Data analysis

Spectral analyses of LFP were performed in MATLAB R2022b (MathWorks) using FieldTrip⁶² and custom-made routines. Only data recorded from adjacent electrode pairs that were unambiguously localized within a clearly defined anatomical region were used (50 out of a total 66 pairs). Due to amplifier artifacts, the first 1,210 samples were removed from each recording, leaving 27 s of continuously recorded LFP for further analysis. Power-line artifacts were removed using a discrete Fourier transform filter at 50 Hz and its second and third harmonics, and an additional band-stop filter at 47–53 Hz. Data were segmented into 1-s epochs, which were visually inspected, manually artifact-rejected, Z-scored (to equalize the contribution of different electrodes across patients), demeaned, Hanning-tapered and Fourier-transformed. Spectral estimates were evaluated for significant differences from baseline at $P < 0.05$ (Fig. 2b), using a non-parametric randomization test, corrected for multiple comparisons, for each brain region across all frequency bins (as previously reported¹⁸). Frequency bands were defined as delta 1–3 Hz, theta 4–7 Hz, alpha 8–12 Hz, beta 13–29 Hz, gamma 30–80 Hz.

PAC analyses (Fig. 3a) were performed on the basis of the cross-frequency coherence between a low-frequency oscillation and the power envelope of a high-frequency oscillation⁶³. The statistical significance of PAC was assessed by 100 repetitions of randomly shifting the signal $>3,000$ data points with regards to the power and recalculating their coherence; the proportion of maximum randomly shifted coherence values obtained that lie above the original coherence value determine the P value.

Additional statistical analyses were Bonferroni-corrected one-way ANOVA with Dunnett's multiple comparisons, Bonferroni-corrected unpaired t -test, Pearson correlation, linear regression and one-tailed Wilcoxon signed-rank test. These analyses were performed using Prism 9.1.2 (GraphPad) and custom-made routines in MATLAB R2022b. The significance level was set at $P < 0.05$.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

The data that support the findings of this study are not openly available to protect patient privacy. Anatomical localization of electrodes was determined using the DISTAL atlas implemented in Lead-DBS toolbox v.2.5.2 MATLAB R2021a.

References

- Denys, D. Pharmacotherapy of obsessive–compulsive disorder and obsessive–compulsive spectrum disorders. *Psychiatr. Clin. N. Am.* **29**, 553–584 (2006).
- Denys, D. et al. Efficacy of deep brain stimulation of the ventral anterior limb of the internal capsule for refractory obsessive–compulsive disorder: a clinical cohort of 70 patients. *Am. J. Psychiatry* **177**, 265–271 (2020).
- Gadot, R. et al. Efficacy of deep brain stimulation for treatment-resistant obsessive–compulsive disorder: systematic review and meta-analysis. *J. Neurol. Neurosurg. Psychiatry* **93**, 1166–1173 (2022).
- Coenen, V. A. et al. The medial forebrain bundle as a target for deep brain stimulation for obsessive–compulsive disorder. *CNS Spectr.* **22**, 282–289 (2017).
- Haber, S. N., Yendiki, A. & Jbabdi, S. Four deep brain stimulation targets for obsessive–compulsive disorder: are they different? *Biol. Psychiatry* **90**, 667–677 (2021).
- Pauls, D. L., Abramovitch, A., Rauch, S. L. & Geller, D. A. Obsessive–compulsive disorder: an integrative genetic and neurobiological perspective. *Nat. Rev. Neurosci.* **15**, 410–424 (2014).
- Saxena, S. & Rauch, S. L. Functional neuroimaging and the neuroanatomy of obsessive–compulsive disorder. *Psychiatr. Clin. North Am.* **23**, 563–586 (2000).
- Figeé, M. et al. Deep brain stimulation restores frontostriatal network activity in obsessive–compulsive disorder. *Nat. Neurosci.* **16**, 386–387 (2013).
- Velikova, S. et al. Dysfunctional brain circuitry in obsessive–compulsive disorder: source and coherence analysis of EEG rhythms. *NeuroImage* **49**, 977–983 (2010).
- Calzà, J. et al. Altered cortico–striatal functional connectivity during resting state in obsessive–compulsive disorder. *Front. Psychiatry* **10**, 319 (2019).
- Barcia, J. A. et al. Personalized striatal targets for deep brain stimulation in obsessive–compulsive disorder. *Brain Stimul.* **12**, 724–734 (2019).
- Sani, O. G. et al. Mood variations decoded from multi-site intracranial human brain activity. *Nat. Biotechnol.* **36**, 954–961 (2018).
- Basu, I. et al. Closed-loop enhancement and neural decoding of cognitive control in humans. *Nat. Biomed. Eng.* **7**, 576–588 (2023).
- Arumugham, S. S. et al. Identification of biomarkers that predict response to subthalamic nucleus deep brain stimulation in resistant obsessive–compulsive disorder: protocol for an open-label follow-up study. *BMJ Open* **11**, e047492 (2021).
- Buzsáki, G., Anastassiou, C. A. & Koch, C. The origin of extracellular fields and currents—EEG, ECoG, LFP and spikes. *Nat. Rev. Neurosci.* **13**, 407–420 (2012).
- Fries, P. Rhythms for cognition: communication through coherence. *Neuron* **88**, 220–235 (2015).
- Sejnowski, T. J. & Paulsen, O. Network oscillations: emerging computational principles. *J. Neurosci.* **26**, 1673–1676 (2006).
- Arbab, T., Battaglia, F. P., Pennartz, C. M. A. & Bosman, C. A. Abnormal hippocampal theta and gamma hypersynchrony produces network and spike timing disturbances in the Fmr1-KO mouse model of Fragile X syndrome. *Neurobiol. Dis.* **114**, 65–73 (2018).
- Sullivan, C. R. P., Olsen, S. & Widge, A. S. Deep brain stimulation for psychiatric disorders: from focal brain targets to cognitive networks. *NeuroImage* **225**, 117515 (2021).
- Rappel, P. et al. Subthalamic theta activity: a novel human subcortical biomarker for obsessive compulsive disorder. *Transl. Psychiatry* **8**, 118 (2018).

21. Olsen, S. T. et al. Case report of dual-site neurostimulation and chronic recording of cortico-striatal circuitry in a patient with treatment refractory obsessive compulsive disorder. *Front. Hum. Neurosci.* **14**, 569973 (2020).
22. Provenza, N. R. et al. Long-term ecological assessment of intracranial electrophysiology synchronized to behavioral markers in obsessive-compulsive disorder. *Nat. Med.* **27**, 2154–2164 (2021).
23. Frank, A. C. et al. Identification of a personalized intracranial biomarker of depression and response to DBS therapy. *Brain Stimul.* **14**, 1002–1004 (2021).
24. Miller, K. J., Prieto, T., Williams, N. R. & Halpern, C. H. Case studies in neuroscience: the electrophysiology of a human obsession in nucleus accumbens. *J. Neurophysiol.* **121**, 2336–2340 (2019).
25. Fridgeirsson, E. A. et al. Patient specific intracranial neural signatures of obsessions and compulsions in the ventral striatum. *J. Neural Eng.* **20**, 026008 (2023).
26. Jensen, O. & Colgin, L. L. Cross-frequency coupling between neuronal oscillations. *Trends Cogn. Sci.* **11**, 267–269 (2007).
27. Horn, A. & Kühn, A. A. Lead-DBS: a toolbox for deep brain stimulation electrode localizations and visualizations. *NeuroImage* **107**, 127–135 (2015).
28. Bertino, S. et al. Spatially coherent and topographically organized pathways of the human globus pallidus. *Hum. Brain Mapp.* **41**, 4641–4661 (2020).
29. Karachi, C. et al. Three-dimensional cartography of functional territories in the human striatopallidal complex by using calbindin immunoreactivity. *J. Comp. Neurol.* **450**, 122–134 (2002).
30. Francois, C. et al. Behavioural disorders induced by external globus pallidus dysfunction in primates II. Anatomical study. *Brain* **127**, 2055–2070 (2004).
31. Lakatos, P., Karmos, G., Mehta, A. D., Ulbert, I. & Schroeder, C. E. Entrainment of neuronal oscillations as a mechanism of attentional selection. *Science* **320**, 110–113 (2008).
32. Schroeder, C. E. & Lakatos, P. Low-frequency neuronal oscillations as instruments of sensory selection. *Trends Neurosci.* **32**, 9–18 (2009).
33. Kajihara, T. et al. Neural dynamics in motor preparation: from phase-mediated global computation to amplitude-mediated local computation. *NeuroImage* **118**, 445–455 (2015).
34. Salkovskis, P. M. Obsessional-compulsive problems: a cognitive-behavioural analysis. *Behav. Res. Ther.* **23**, 571–583 (1985).
35. Robbins, T. W., Gillan, C. M., Smith, D. G., De Wit, S. & Ersche, K. D. Neurocognitive endophenotypes of impulsivity and compulsivity: towards dimensional psychiatry. *Trends Cogn. Sci.* **16**, 81–91 (2012).
36. Russo, M. et al. Obsessive-compulsive disorder: a ‘sensory-motor’ problem? *Int. J. Psychophysiol.* **92**, 74–78 (2014).
37. Eijsker, N., van Wingen, G., Smolders, R., Smit, D. J. A. & Denys, D. Exploring the role of the nucleus accumbens in adaptive behavior using concurrent intracranial and extracranial electrophysiological recordings in humans. *eNeuro* **7**, ENEURO.0105-20.2020 (2020).
38. Schwabe, K. et al. Oscillatory activity in the BNST/ALIC and the frontal cortex in OCD: acute effects of DBS. *J. Neural Transm.* **128**, 215–224 (2021).
39. Smith, E. E. et al. A brief demonstration of frontostriatal connectivity in OCD patients with intracranial electrodes. *NeuroImage* **220**, 117138 (2020).
40. Saxena, S., Brody, A. L., Schwartz, J. M. & Baxter, L. R. Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. *Br. J. Psychiatry Suppl.* 26–37 (1998).
41. Laplane, D., Baulac, M., Widlocher, D. & Dubois, B. Pure psychic akinesia with bilateral lesions of basal ganglia. *J. Neurol. Neurosurg. Psychiatry* **47**, 377–385 (1984).
42. Laplane, D. et al. Obsessive-compulsive and other behavioural changes with bilateral basal ganglia lesions: a neuropsychological, magnetic resonance imaging and positron tomography study. *Brain* **112**, 699–725 (1989).
43. Escalona, P. R., Adair, J. C., Roberts, B. B. & Graeber, D. A. Obsessive-compulsive disorder following bilateral globus pallidus infarction. *Biol. Psychiatry* **42**, 410–412 (1997).
44. Endres, D. et al. Obsessive-compulsive symptoms in two patients with strategic basal ganglia lesions. *Mol. Psychiatry* **28**, 528–531 (2023).
45. Piantadosi, S. C. et al. Hyperactivity of indirect pathway-projecting spiny projection neurons promotes compulsive behavior. *Nat. Commun.* **15**, 4434 (2024).
46. Lopes da Silva, F. EEG and MEG: relevance to neuroscience. *Neuron* **80**, 1112–1128 (2013).
47. Bahramisharif, A. et al. Deep brain stimulation diminishes cross-frequency coupling in obsessive-compulsive disorder. *Biol. Psychiatry* **80**, e57–e58 (2016).
48. Mercier, M. R. et al. Evaluation of cortical local field potential diffusion in stereotactic electro-encephalography recordings: a glimpse on white matter signal. *NeuroImage* **147**, 219–232 (2017).
49. Alonso, P. et al. Deep brain stimulation for obsessive-compulsive disorder: a meta-analysis of treatment outcome and predictors of response. *PLoS ONE* **10**, e0133591 (2015).
50. Li, N. et al. A unified connectomic target for deep brain stimulation in obsessive-compulsive disorder. *Nat. Commun.* **11**, 3364 (2020).
51. Scangos, K. W., Makhoul, G. S., Sugrue, L. P., Chang, E. F. & Krystal, A. D. State-dependent responses to intracranial brain stimulation in a patient with depression. *Nat. Med.* **27**, 229–231 (2021).
52. Scangos, K. W. et al. Closed-loop neuromodulation in an individual with treatment-resistant depression. *Nat. Med.* **27**, 1696–1700 (2021).
53. Shivacharan, R. S. et al. Pilot study of responsive nucleus accumbens deep brain stimulation for loss-of-control eating. *Nat. Med.* **28**, 1791–1796 (2022).
54. Goodman, W. K. et al. The Yale-Brown Obsessive Compulsive Scale. II. Validity. *Arch. Gen. Psychiatry* **46**, 1012–1016 (1989).
55. Avants, B., Epstein, C., Grossman, M. & Gee, J. Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. *Med. Image Anal.* **12**, 26–41 (2008).
56. Fonov, V. et al. Unbiased average age-appropriate atlases for pediatric studies. *NeuroImage* **54**, 313–327 (2011).
57. Husch, A., Petersen, M. V., Gemmar, P., Goncalves, J. & Hertel, F. PaCER—a fully automated method for electrode trajectory and contact reconstruction in deep brain stimulation. *NeuroImage Clin.* **17**, 80–89 (2018).
58. Ewert, S. et al. Toward defining deep brain stimulation targets in MNI space: a subcortical atlas based on multimodal MRI, histology and structural connectivity. *NeuroImage* **170**, 271–282 (2018).
59. Ding, S. et al. Comprehensive cellular-resolution atlas of the adult human brain. *J. Comp. Neurol.* **524**, 3127–3481 (2016).
60. Mai, J. K., Majtanik, M. & Paxinos, G. *Atlas of the Human Brain* (Elsevier, 2015).
61. Treu, S. et al. Deep brain stimulation: imaging on a group level. *NeuroImage* **219**, 117018 (2020).
62. Oostenveld, R., Fries, P., Maris, E. & Schoffelen, J.-M. FieldTrip: open source software for advanced analysis of MEG, EEG, and invasive electrophysiological data. *Comput. Intell. Neurosci.* **2011**, 156869 (2011).
63. Osipova, D., Hermes, D. & Jensen, O. Gamma power is phase-locked to posterior alpha activity. *PLoS ONE* **3**, e3990 (2008).

Acknowledgements

This work was funded by an Amsterdam Brain & Cognition Initiative Project grant to T.A. We thank A. Bahramisharif for assistance with the study, O. Jensen for discussions on cross-frequency coupling and G. Legrande at Medtronic for technical support. DBS devices were provided by Medtronic for research purposes. Medtronic had no role in study design, data analysis or interpretation of findings.

Author contributions

D.D., M.F. and M.N.B. conceived the experiment, and together with I.O.B., P.v.d.M. and P.R.S. carried it out; T.A. and I.W. designed and carried out the data analysis; T.A. wrote the paper.

Competing interests

D.D. and P.R.S. receive occasional in-kind research support from Medtronic. P.R.S. acts as an independent consultant for Medtronic, Boston Scientific and Elekta. All other authors declare no competing interests.

Additional information

Extended data are available for this paper at <https://doi.org/10.1038/s44220-025-00457-9>.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s44220-025-00457-9>.

Correspondence and requests for materials should be addressed to Tara Arbab or Damiaan Denys.

Peer review information *Nature Mental Health* thanks Paul Mosley, Nicole Provenza and Chencheng Zhang for their contribution to the peer review of this work.


Reprints and permissions information is available at www.nature.com/reprints.


Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.


© The Author(s) 2025

Tara Arbab ^{1,2,3,4,7} , **Melisse N. Bais** ^{1,2,3,7}, **Martijn Figee** ⁵, **Isidoor O. Bergfeld** ^{1,2,3}, **P. Richard Schuurman**⁶, **Pepijn van den Munckhof**⁶, **Ingo Willuhn**^{1,2,3,4} & **Damiaa Denys** ^{1,2} 

¹Department of Psychiatry, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. ²Amsterdam Neuroscience, Amsterdam, The Netherlands. ³Amsterdam Brain and Cognition, University of Amsterdam, Amsterdam, The Netherlands. ⁴Netherlands Institute for Neuroscience, Royal Netherlands Academy of Arts and Sciences, Amsterdam, The Netherlands. ⁵Nash Family Center for Advanced Circuit Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ⁶Department of Neurosurgery, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands. ⁷These authors contributed equally: Tara Arbab, Melisse N. Bais.  e-mail: t.arbab@amsterdamumc.nl; d.denys@amsterdamumc.nl



Extended Data Fig. 1 | Power spectra (mean \pm SEM) of LFP recorded during the experimental states in the pooled $n=16$ electrode pairs that were excluded from analysis as their placement fell wholly or partially across anatomical borders. Compare to Fig. 2b.



Extended Data Fig. 2 | Bar graphs (mean+SEM) of spectral LFP power in delta and alpha frequency bands during the experimental states in each brain region. Left, duplicated from Fig. 2c: pairwise comparisons mark significantly different power during obsession, compulsion, and relief from baseline (Bonferroni-corrected one-way ANOVA with Dunnett’s multiple comparisons

test). Right, same data as Left, but plotted on the basis of individual patients. Although the number of patients in each anatomical group is relatively low (ALIC n=5, aGPe n=7, pGPe n=6, aIAC n=3, NAc n=4), the results (not analyzed statistically) still follow our original conclusions, that compulsions increase low-frequency LFP power compared with baseline.

Extended Data Table 1 | Number of samples for each frequency bin in Fig. 2b

FIGURE 2B NUMBER OF SAMPLES

Brain region	Baseline	Obsession	Compulsion	Relief
ALIC	1004	1108	969	996
aGPe	1255	1291	1702	1191
pGPe	1783	1769	1569	1690
alAC	628	675	487	575
NAc	491	512	775	491

Extended Data Table 2 | Statistics for Fig. 2c Bonferroni-corrected one-way ANOVA with Dunnett's multiple comparisons

FIGURE 2C STATISTICS				
Brain region	Frequency band	Anova	Dunnett's multiple comparison	Effect size
ALIC	δ	F (3, 4073) = 14.63, p < 0.0001	BAS vs COM 95% CI -0.03153 to -0.01155, p < 0.0001 BAS vs REL 95% CI -0.03105 to -0.01121, p < 0.0001	0.7622 0.7477
	θ	F (3, 4073) = 21.91, p < 0.0001	BAS vs COM 95% CI -0.01169 to -0.005739, p < 0.0001 BAS vs REL 95% CI -0.007616 to -0.001703, p = 0.0006	0.9924 0.5302
aGPe	α	F (3, 4073) = 9.874, p < 0.0001	BAS vs COM 95% CI -0.002435 to -0.0005882, p = 0.0004	0.3120
	δ	F (3, 5435) = 173.9, p < 0.0001	BAS vs COM 95% CI -0.09640 to -0.07381, p < 0.0001	1.0251
	θ	F (3, 5435) = 210.6, p < 0.0001	BAS vs COM 95% CI -0.03243 to -0.02535, p < 0.0001	1.4155
pGPe	α	F (3, 5435) = 67.26, p < 0.0001	BAS vs COM 95% CI -0.005833 to -0.003772, p < 0.0001	0.5618
	β	F (3, 5435) = 14.08, p < 0.0001	BAS vs COM 95% CI -0.0007131 to -0.0002247, p < 0.0001	0.1678
	δ	F (3, 6807) = 28.66, p < 0.0001	BAS vs COM 95% CI -0.02838 to -0.01464, p < 0.0001	0.3474
alAC	θ	F (3, 6807) = 32.74, p < 0.0001	BAS vs COM 95% CI -0.009770 to -0.005884, p < 0.0001	0.5578
	α	F (3, 6807) = 11.35, p < 0.0001	BAS vs COM 95% CI -0.002125 to -0.0008903, p < 0.0001	0.2502
	β	F (3, 6807) = 11.42, p < 0.0001	BAS vs COM 95% CI -0.0005296 to -0.0002128, p < 0.0001	0.2125
NAC	δ	F (3, 2361) = 11.38, p < 0.0001	BAS vs COM 95% CI -0.06004 to -0.02164, p < 0.0001	0.5392
	α	F (3, 2361) = 8.800, p < 0.0001	BAS vs COM 95% CI -0.003583 to -0.001109, p < 0.0001	0.3844
NAC	δ	F (3, 2265) = 123.6, p < 0.0001	BAS vs COM 95% CI -0.1510 to -0.1110, p < 0.0001	2.6630
	θ	F (3, 2265) = 197.0, p < 0.0001	BAS vs COM 95% CI -0.04901 to -0.03810, p < 0.0001	2.6787
	α	F (3, 2265) = 166.8, p < 0.0001	BAS vs COM 95% CI -0.01536 to -0.01170, p < 0.0001	2.6553
	β	F (3, 2265) = 151.0, p < 0.0001	BAS vs COM 95% CI -0.005192 to -0.003908, p < 0.0001	3.7418
	γ	F (3, 2265) = 83.73, p < 0.0001	BAS vs COM 95% CI -0.0006855 to -0.0004726, p < 0.0001	1.7942

Extended Data Table 3 | Statistics for Fig. 2d delta Bonferroni-corrected unpaired t-test

FIGURE 2D STATISTICS δ

Brain region	Baseline vs Motor	Effect size	Baseline vs Non-motor	Effect size
ALIC	t(1432) = 8.184, 95% CI 0.01375 to 0.02243, p < 0.0001	0.6440	t(537) = 3.017, 95% CI 0.01051 to 0.04976, p < 0.0027	1.0465
aGPe	t(2298) = 13.83, 95% CI 0.08408 to 0.1119, p < 0.0001	1.1615	t(655) = 3.632, 95% CI 0.01614 to 0.05413, p < 0.0003	0.4462
pGPe	t(1944) = 5.321, 95% CI 0.01167 to 0.02530, p < 0.0001	0.2764	t(1404) = 4.801, 95% CI 0.01561 to 0.03718, p < 0.0001	0.4749
aiAC	t(1113) = 4.186, 95% CI 0.02170 to 0.05998, p < 0.0001	0.5392	-	-
NAc	t(1052) = 12.44, 95% CI 0.1306 to 0.1795, p < 0.0001	2.9403	t(210) = 0.3585, 95% CI -0.008835 to 0.01276, p = 0.7203	0.0687

Extended Data Table 4 | Statistics for Fig. 2d alpha Bonferroni-corrected unpaired t-test

FIGURE 2D STATISTICS α

Brain region	Baseline vs Motor	Effect size	Baseline vs Non-motor	Effect size
ALIC	t(1432) = 7.573, 95% CI 0.001583 to 0.002690, p < 0.0001	0.5599	t(537) = 0.2456, 95% CI -0.001994 to 0.001551, p = 0.8061	-0.0327
aGPe	t(2298) = 10.99, 95% CI 0.004991 to 0.007159, p < 0.0001	1.6515	t(655) = 1.216, 95% CI -0.001009 to 0.004290, p = 0.2246	0.1128
pGPe	t(1944) = 3.802, 95% CI 0.0006399 to 0.002004, p = 0.0001	0.2039	t(1404) = 4.174, 95% CI 0.001020 to 0.002828, p < 0.0001	0.3533
aIAC	t(1113) = 3.634, 95% CI 0.001069 to 0.003578, p = 0.0003	0.3844	-	-
NAc	t(1052) = 13.79, 95% CI 0.01408 to 0.01875, p < 0.0001	6.3715	t(210) = 0.4103, 95% CI -0.002212 to 0.001450, p = 0.6820	-0.0582

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection

Data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The data that support the findings of this study are not openly available to protect patient privacy. Anatomical localization of electrodes was determined using the DISTAL atlas implemented in Lead-DBS toolbox v2.5.2 Matlab R2021a (the MathWorks).

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender	Gender was determined based on self-report in clinical files. No gender-based analyses were performed. Gender demographics are reported in Table 1.
Reporting on race, ethnicity, or other socially relevant groupings	No data on race, ethnicity, or other socially-relevant groupings was collected.
Population characteristics	Age and handedness were determined based on self-report. Patient age range was 32-68 years (mean 49, standard deviation 10.9). Age and handedness demographics are reported in Table 1.
Recruitment	Patients were recruited with treatment-resistant OCD, following a new indication for DBS or indication for stimulator replacement after successful DBS. These patients were the first to be implanted with the newly available Medtronic model 37604 Activa PC+S sensing neurostimulator; there was no selection bias in this recruitment.
Ethics oversight	Medical Ethics Committee of the Academic Medical Center, University of Amsterdam

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	A total of 11 patients were included. Sample-size was not predetermined based on any statistical method. Sample size depended on the number of patients with treatment-resistant OCD indicated for DBS. This is a large cohort an exploratory study of this kind where intracranial recordings are compared within-subject.
Data exclusions	Data was only excluded due to technical errors, i.e. if recording failed during data collection.
Replication	Recordings were replicated for each patient (except one) four times.
Randomization	Findings of this study are observational. Covariates were controlled by comparing intracranial recordings within-subject.
Blinding	Blinding was not possible in this study as all participants are patients with treatment-resistant OCD, and all recordings were intended to capture intracranial data during provoked symptoms.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> Antibodies
<input checked="" type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input type="checkbox"/>	<input checked="" type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern
<input checked="" type="checkbox"/>	<input type="checkbox"/> Plants

Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

Clinical trial registration	Netherlands Trial Register number NL7486
Study protocol	Protocols can be accessed via the Medical Ethics Committee of the Academic Medical Center, University of Amsterdam
Data collection	Patients were recruited between June 2015 and March 2020 at the outpatient clinic of the Psychiatry department of the Amsterdam UMC. The experiment was conducted in the clinic.
Outcomes	Findings of this study are observational. There were no outcomes of treatment assessed.

Plants

Seed stocks	<i>Report on the source of all seed stocks or other plant material used. If applicable, state the seed stock centre and catalogue number. If plant specimens were collected from the field, describe the collection location, date and sampling procedures.</i>
Novel plant genotypes	<i>Describe the methods by which all novel plant genotypes were produced. This includes those generated by transgenic approaches, gene editing, chemical/radiation-based mutagenesis and hybridization. For transgenic lines, describe the transformation method, the number of independent lines analyzed and the generation upon which experiments were performed. For gene-edited lines, describe the editor used, the endogenous sequence targeted for editing, the targeting guide RNA sequence (if applicable) and how the editor was applied.</i>
Authentication	<i>Describe any authentication procedures for each seed stock used or novel genotype generated. Describe any experiments used to assess the effect of a mutation and, where applicable, how potential secondary effects (e.g. second site T-DNA insertions, mosaicism, off-target gene editing) were examined.</i>